July 31, 2022Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors Read more »
June 2, 2022Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD L1 IHC Read more »
March 17, 2022PD-L1 expression by RNA-sequencing and survival from pembrolizumab in non-small cell lung cancer (NSCLC) Read more »
March 21, 2022Cancer testis antigen burden: pan-cancer distribution and survival implications Read more »
